<DOC>
	<DOCNO>NCT01427738</DOCNO>
	<brief_summary>The purpose study see one two medicine ( topical gentian violet [ GV ] nystatin oral suspension ) well treat Oral Candidiasis ( OC ) . This measure whether study participant still OC sores his/her mouth 14 day treatment . Also , safety tolerability GV nystatin treatment OC assess .</brief_summary>
	<brief_title>Gentian Violet Vs. Nystatin Oral Suspension Treatment Oropharyngeal Candidiasis</brief_title>
	<detailed_description>A5265 phase III , open-label ( researcher participant know treatment administer ) clinical trial compare safety efficacy topical GV oral nystatin suspension . Male female HIV-1 positive participant ≥ 18 year age randomize ( toss coin ) equal probability stratify CD4+ T-cell count use antiretroviral therapy time study entry receive either topical GV solution ( 5 mL swish gargle 1 minute spit two time daily ) nystatin oral suspension ( 5 mL swish 1 minute swallow four time daily ) 14 day . Therapy consider fail participant clinical improvement ( assessed severity pseudomembranous candidiasis ) either treatment regimen . Evaluation sign symptom oral candidiasis do evaluator blind treatment assignment . A total 494 participant expect enroll study due early study closure 221 enrol ; participant expect study 13 week .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<mesh_term>Gentian Violet</mesh_term>
	<criteria>HIV1 infection , document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 antigen , plasma HIV1 RNA viral load . Pseudomembranous candidiasis document complete oral exam ( i.e. , white yellow spot plaque underlie erythematous base , locate part oral cavity ) screen visit . Participants document angular chelitis and/or erythematous candidiasis without pseudomembranous candidiasis eligible enroll study . If antiretroviral therapy ( ART ) , initiation regimen least 12 week prior study entry , willingness participant remain current ART regimen studydefined 14day treatment period complete . NOTE : Participants ARTnaïve ART eligible participate study intend initiate ART study define 14day treatment period . CD4+ cell count obtain within 30 day prior study entry DAIDSapproved laboratory . Documented presumptive sign symptom esophageal candidiasis ( e.g. , dysphagia ) screen period unless endoscopic examination esophagus perform , fungal esophagitis exclude . Use investigational drug currently within 30 day prior study entry . NOTE : For purpose study , drug available FDAauthorized expand access program NOT consider investigational . Concurrent vaginal candidiasis within 21 day prior study entry . Use inhale systemic corticosteroid within 14 day prior study entry . Use antifungal agent within 30 day prior study entry . Anticipated need systemic oral/topical antifungal agent diagnose within studydefined 14day treatment period . Intend initiate ART screening period , study entry , within studydefined 14day treatment period . Intend use additional oral topical treatment within study define 14day treatment period . Known allergy/sensitivity hypersensitivity component study drug formulation . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness , opinion site investigator , require systemic treatment . Hospitalization within 30 day prior study entry HIV HIVrelated condition . Previous current history porphyria . Presence oral wart screen period study entry visit randomization . Current wear full denture maxillary partial denture study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>